✦ LIBER ✦

CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia

✍ Scribed by van der Heijden, Pieter F.M.; de Wit, Willem; Brownell, Judith; Schoemaker, Joop; Rolland, Rune

Book ID: 122919902
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 729 KB
Volume: 40
Category: Article
ISSN: 0301-2115
DOI: 10.1016/0028-2243(91)90101-P

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A DOUBLE-BLIND STUDY COMPARING A NEW NON

A DOUBLE-BLIND STUDY COMPARING A NEW NON-ERGOT, LONG-ACTING DOPAMINE AGONIST, CV 205-502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINAEMIA

✍ ROY HOMBURG; CHRISTINE WEST; JUDITH BROWNELL; HOWARD S. JACOBS 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 477 KB

LONG-TERM TREATMENT WITH A NEW NON-ERGOT

LONG-TERM TREATMENT WITH A NEW NON-ERGOT LONG-ACTING DOPAMINE AGONIST, CV 205-502, IN WOMEN WITH HYPERPROLACTINAEMIA

✍ CARSTEN RASMUSSEN; TORBJÖRN BERGH; LEIF WIDE; JUDITH BROWNELL 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 539 KB

Acute overdose of a new dopamine agonist

Acute overdose of a new dopamine agonist, CV 205-502

✍ Igor Tauveron; Jean-Michel Gesta; Isabelle Jalenques; Philippe Thiebiot 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

CV205–502, A NEW NON-ERGOT DOPAMINE AGON

CV205–502, A NEW NON-ERGOT DOPAMINE AGONIST, REDUCES PROLACTINOMA SIZE IN MAN

✍ P. S. BARNETT; J. M. DAWSON; J. BUTLER; P. B. COSKERAN; J. J. MACCABE; A. M. McG 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 692 KB

Disappearance of a pituitary tumor after

Disappearance of a pituitary tumor after 15 months of treatment with CV 205–502, a new dopamine agonist

✍ Faβbender, W. J. ;Stracke, H. ;Bachmann, G. ;Rau, W. ;Federlin, K. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 482 KB

We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Immediately after diagnosis of a 12 x 10 mm intrasellar prolactinoma, treatment with CV 205-502 was begun at a daily dose o

Effect of the new dopaminergic agonist C

Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas

✍ L. Duranteau; P. Chanson; A. Lavoinne; S. Horlait; J. Lubetzki; J. M. Kuhn 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB